# A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)

> **NCT07408063** · PHASE2 · RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 30 (estimated)

## Conditions studied

- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** GSK5764227
- **DRUG:** Dostarlimab

## Key facts

- **NCT ID:** NCT07408063
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-27
- **Primary completion:** 2030-06-30
- **Final completion:** 2031-03-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07408063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07408063, "A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07408063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*